prikaz prve stranice dokumenta Novi antikoagulantni lijekovi
  Download
PDF 605.24 KB
master's thesis
Novi antikoagulantni lijekovi
Zagreb: University of Zagreb, School of Medicine, 2016. urn:nbn:hr:105:610436
Slišković, Ana Marija
University of Zagreb
School of Medicine
Department of Internal Medicine

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Slišković, A. M. (2016). Novi antikoagulantni lijekovi (Master's thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:610436

Slišković, Ana Marija. "Novi antikoagulantni lijekovi." Master's thesis, University of Zagreb, School of Medicine, 2016. https://urn.nsk.hr/urn:nbn:hr:105:610436

Slišković, Ana Marija. "Novi antikoagulantni lijekovi." Master's thesis, University of Zagreb, School of Medicine, 2016. https://urn.nsk.hr/urn:nbn:hr:105:610436

Slišković, A. M. (2016). 'Novi antikoagulantni lijekovi', Master's thesis, University of Zagreb, School of Medicine, accessed 22 November 2024, https://urn.nsk.hr/urn:nbn:hr:105:610436

Slišković AM. Novi antikoagulantni lijekovi [Master's thesis]. Zagreb: University of Zagreb, School of Medicine; 2016 [cited 2024 November 22] Available at: https://urn.nsk.hr/urn:nbn:hr:105:610436

A. M. Slišković, "Novi antikoagulantni lijekovi", Master's thesis, University of Zagreb, School of Medicine, Zagreb, 2016. Available at: https://urn.nsk.hr/urn:nbn:hr:105:610436

Metadata
TitleNovi antikoagulantni lijekovi
Title (english)New anticoagulant drugs
AuthorAna Marija Slišković
MentorIveta Šimić (mentor)
Committee memberSilva Zupančić-Šalek (predsjednik povjerenstva)
Committee memberJasenka Markeljević (član povjerenstva)
Committee memberIveta Šimić (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Zagreb
Defense date and country2016-07-15, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract
Novi oralni antikoagulansi učinkovita su mjera prevencije i liječenja tromboembolijskih bolesti za koje se vezuje visok morbiditet i mortalitet. Mehanizam njihovog djelovanja temeljen je bilo na inhibiciji trombina ili inhibiciji aktivnog faktora X. Lijekovi su visoke učinkovitosti, povoljnih farmakokinetičkih svojstava, s manjom incidencijom zabilježenih nuspojava u odnosu na alternativnu antikoagulaciju varfarinom. Nuspojave se javljaju kao rezultat djelovanja lijeka na zgrušavanje krvi i mogu biti od rijetkih i životno ugrožavajućih do blažih i čestih krvarenja. Od direktnih inhibitora trombina značajan je dabigatran, a u inhibitore faktora Xa ubrajamo apiksaban i rivaroksaban. ----- Za razliku od vitamina K koji možemo primijeniti kao antidot u slučaju predoziranja varfarinom, specifične molekule koje poništavaju učinak NOAC-a još su u fazi razvoja ili su nedavno odobrene pa zbog toga nisu dostupne u svakodnevnom radu. Mjere opreza potrebne su kod bubrežnih bolesnika, starijih bolesnika, onih sa umjetnim zaliscima, prirođenim koagulopatijama ili bilo kojim drugim stanjima koje povećavaju rizik krvarenja. Prije propisivanja NOAC-a, liječnik bi se trebao upoznati s postojećim komorbiditetima i ostalom terapijom koju pacijent konzumira jer to može imati utjecaja na učinkovitost NOAC-a. Uz adekvatno korištenje te edukaciju bolesnika i članova obitelji o pravilnom doziranju i važnosti strogog pridržavanja antikoagulantne terapije, NOAC-i su lijekovi sigurnog profila.
Abstract (english)
New oral anticoagulants are effective measures of prevention and treatment of thromboembolic disease that is associated with both: high morbidity and mortality. Their mechanism of action is based on the inhibition of thrombin, or active factor X. These drugs have high efficiency, favorable pharmacokinetic parameters, with lower incidence of reported side effects compared to alternative anticoagulation with warfarin. Side effects can occur due to action of the drug on blood clotting and may vary from rare and life-threatening to mild and frequent bleeding. Dabigatran is an important direct thrombin inhibitor, while in factor Xa inhibitors we include rivaroxaban and apixaban. ----- Unlike vitamin K, which can be used as an antidote for an overdose of warfarin, specific molecules that can reversed the effect of NOAC are still explored or have been recently approved and therefore they are not available in daily clinical practice. Precautions are needed in patients with kidney failure, the elderly, those with artificial heart valves, congenital coagulopathy or any other conditions that increase the risk of bleeding. Before prescribing NOAC, a physician should be familiar with the existing co-morbidities and other consumed therapy because it can affect the performance of NOAC's. With appropriate use and education of patients and family members about the proper dosage and the importance of strict adherence to anticoagulation therapy, NOAC ̓s are medicines with safe profile.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:105:610436
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2017-07-05 12:01:41